Multiple Myeloma

Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

Jeffrey Zonder, MD, discusses the need for increased screening for patients who are at higher risk of developing multiple myeloma.

Paul G. Richardson, MD, discusses 2 quadruplet regimens for the treatment of patients with newly diagnosed multiple myeloma and changes in administration.

Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.

Kiavasch Mohammad Nejad Farid, MD, discusses how compassionate use of MDC-CAR-BCMA001 could address unmet needs for multiple myeloma and AL amyloidosis.

Joshua Richter, MD, discusses the identification of early abnormalities that may indicate that a patient has multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses the future clinical development of ciltacabtagene autoleucel in multiple myeloma.

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.

Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

Bhagirathbhai Dholaria, MBBS, discusses the rationale and evolving investigation of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes.

Jeffrey Zonder, MD, discusses the current epidemiological landscape of multiple myeloma in the United States.

Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

The European Commission approved subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma, regardless of transplant eligibility.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.

Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.

D-VRd with daratumumab/lenalidomide maintenance led to sustained PFS and MRD negativity across high-risk subgroups of newly diagnosed multiple myeloma.